UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/512,138	06/14/2005	David John Moody	056258-5078	6844
, - <del>-</del>	7590 03/17/200 VIS & BOCKIUS LLP		EXAMINER	
	LVANIA AVENUE N		ASINOVSKY, OLGA	
WASHINGTON, DC 20004			ART UNIT	PAPER NUMBER
			1796	
			MAIL DATE	DELIVERY MODE
			03/17/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/512,138	MOODY ET AL.				
Office Action Summary	Examiner	Art Unit				
	OLGA ASINOVSKY	1796				
The MAILING DATE of this communication app	ears on the cover sheet with the c	orrespondence address				
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 22 O	ctober 2004.					
	action is non-final.					
3) Since this application is in condition for allowar						
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	53 O.G. 213.				
Disposition of Claims						
4)⊠ Claim(s) <u>1-13</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-13</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	r election requirement.					
Application Papers						
9)☐ The specification is objected to by the Examine	r.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correct		, ,				
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a)⊠ All b)□ Some * c)□ None of: 1.⊠ Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
	·					
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) 🔲 Interview Summary					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da 5) Notice of Informal P					
Information Disclosure Statement(s) (PTO/SB/08)     Paper No(s)/Mail Date	6) Other:	aton Application				

Application/Control Number: 10/512,138 Page 2

Art Unit: 1796

## **DETAILED ACTION**

## Claim Rejections - 35 USC § 112

- 1. Claims 1-13 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
- Claim 1. A process for the preparation of an oligonucleotide which comprises the assembly of an oligonucleotide attached to a solid support is indefinite, because there is no definition of an oligonucleotide and there is no step of a process condition to identify term "attached." A step of preparing a solid support is not clear, there is no process condition how to prepare a solid support. There is no definition of a polymerizable unit. The phrase "an acid-labile protecting group, preferably an optionally substituted trityl group" is not clear and confusing: there is no definition of "acid-labile protecting group."
- Claim 2. There are no definitions for  $R^1$  and  $R^5$ , a monomer of formula (1) is indefinite.
- Claim 4. A condition to produce cross-linking effect is not clear.
- Claim 5. A process wherein the oligonucleotide is assembled by the phosphoramidite <a href="mailto:approach">approach</a> is indefinite. The presence of specified phosphoramidite as an oligonucleotide is not clear.
- Claims 3, 6-9 are rejected in light of their dependency directly or indirectly upon the rejected above claims.
- Claim 10. A composition of matter having the formula Ps-Z-Q is unclear. There is no definition of a polymerizable unit. The term "attached" is not clear. The phrase "an acid-

labile protecting group, preferably an optionally substituted trityl group" is not clear, the scope of the claimed protective group is not easily determined. There is no definition of a cleavable linker for Z in claim 10. The presence of a protecting group, a nucleoside or an oligonucleotide for Q is not clear. What is the difference between an acid-labile protecting group for Ps polymer chain and Q protecting group? A chemical formulation of a composition in claim 10 is indefinite.

Claims 11-13 are rejected in light of their dependency directly or indirectly upon the rejected claim 10 above.

## Claim Rejections - 35 USC § 103

- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 3. Claims 1-13 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO 00/02953 (inventor Main, Brian) in view of Reddy et al U.S. patent 5,869,696.

WO 00/02953 is cited under X category in applicants' search report. Reference Patent 6,395,842 to Main belongs to the patent family to WO 00/02953. Reference Patent 5,869,696 is also cited under X category in applicants' search report.

Main discloses a solid polymer support containing polyoxyalkylenes. The hydroxypolyC2-4alkyleneoxy chain is readable in the present claims, page 1, lines 31-

37. The hydroxyl group is protected by the presence of a polymerizable monomer such as hydroxystyrene, styrene, hydroxyethyl (meth)acrylate, page 2, lines 3-26 to produce cross-linking. Also, the terminal hydroxyl group is protected by a group selected from the group consisting of acetyl, benzyl, benzoyl, tri(alkyl)silyl and tetrahydropyranyl groups, claim 4 at page 14. The tetrahydropyranyl group may be removed with p-toluene sulphonic acid, page 6, lines 21-22. Although WO'953 does not mention an acid-labile protecting group, the evidence about presence of acid-labile group is within the teaching that tetrahydropyranyl group may be removed with p-toluene sulphonic acid.

WO'953 does not disclose an oligonucleotide attached to a solid support.

Reddy discloses oligonucleotide reagent attached to a solid support via a phosphoramidite linkage, column 4, line 27 and column 3, lines 40-65, for the present claim 5. The phosphoramidite linkage of the oligonucleotide does not effect the solid support bond, such that oligonucleotide intact on the solid support, column 3, lines 63-65 and column 8, line 18.

It would have been obvious to one of ordinary skill in the art to use a process for producing oligonulcleotide synthesis reagent attached to a solid support in Reddy invention with a solid support by teaching in WO'953 because the oligonucleotide having phosphoramidite linkage group does not effect the solid support bond in Reddy invention, therefore, any solid support material works equally well within the same expectation.

Application/Control Number: 10/512,138 Page 5

Art Unit: 1796

4. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. The closest references under X category have been considered above.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to OLGA ASINOVSKY whose telephone number is (571)272-1066. The examiner can normally be reached on 9:00 to 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Randy Gulakowski can be reached on 571-272-1302. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/O.A./ March 02, 2008 Application/Control Number: 10/512,138 Page 6

Art Unit: 1796

/Randy Gulakowski/

Supervisory Patent Examiner, Art Unit 1796